25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CMVLF (Cellectis) Stock Analysis
Buy, Hold or Sell?

Let's analyze Cellectis together

I guess you are interested in Cellectis S.A. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Cellectis’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Cellectis’s Price Targets

I'm going to help you getting a better view of Cellectis S.A. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Cellectis S.A

I send you an email if I find something interesting about Cellectis S.A.

1. Quick Overview

1.1. Quick analysis of Cellectis (30 sec.)










1.2. What can you expect buying and holding a share of Cellectis? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$1.31
Expected worth in 1 year
$1.77
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$0.46
Return On Investment
37.1%

For what price can you sell your share?

Current Price per Share
$1.25
Expected price per share
$1.25 - $1.25
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Cellectis (5 min.)




Live pricePrice per Share (EOD)
$1.25
Intrinsic Value Per Share
$-8.78 - $8.39
Total Value Per Share
$-7.47 - $9.70

2.2. Growth of Cellectis (5 min.)




Is Cellectis growing?

Current yearPrevious yearGrowGrow %
How rich?$131m$94.4m$30.4m24.4%

How much money is Cellectis making?

Current yearPrevious yearGrowGrow %
Making money-$9.2m-$25.5m$16.3m176.6%
Net Profit Margin-71.0%-13,510.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Cellectis (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#318 / 908

Most Revenue
#288 / 908

Most Profit
#476 / 908

Most Efficient
#487 / 908
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Cellectis?

Welcome investor! Cellectis's management wants to use your money to grow the business. In return you get a share of Cellectis.

First you should know what it really means to hold a share of Cellectis. And how you can make/lose money.

Speculation

The Price per Share of Cellectis is $1.25. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cellectis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cellectis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.31. Based on the TTM, the Book Value Change Per Share is $0.12 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cellectis.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.064.7%-0.09-7.4%-0.21-16.5%-0.21-16.9%-0.20-15.6%
Usd Book Value Change Per Share0.021.3%0.129.3%-0.10-8.3%-0.11-9.0%0.011.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.3%0.000.1%0.000.0%
Usd Total Gains Per Share0.021.3%0.129.3%-0.10-8.0%-0.11-8.9%0.021.2%
Usd Price Per Share1.50-2.29-2.22-8.46-10.87-
Price to Earnings Ratio6.34-3.23--3.43--5.46--7.68-
Price-to-Total Gains Ratio93.31-41.15--4.96--9.22--55.61-
Price to Book Ratio1.15-1.94-2.44-3.53-3.64-
Price-to-Total Gains Ratio93.31-41.15--4.96--9.22--55.61-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.25
Number of shares800
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.12-0.11
Usd Total Gains Per Share0.12-0.11
Gains per Quarter (800 shares)92.73-88.79
Gains per Year (800 shares)370.91-355.16
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
103713614-359-365
207427327-718-720
301113110311-1076-1075
401484147414-1435-1430
501855184518-1794-1785
602225221622-2153-2140
702596258725-2511-2495
802967295829-2870-2850
903338332932-3229-3205
1003709370036-3588-3560

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%2.010.00.016.7%3.017.00.015.0%5.035.00.012.5%7.042.00.014.3%
Book Value Change Per Share3.01.00.075.0%4.08.00.033.3%6.014.00.030.0%13.027.00.032.5%19.030.00.038.8%
Dividend per Share0.00.04.00.0%2.00.010.016.7%2.00.018.010.0%2.00.038.05.0%2.00.047.04.1%
Total Gains per Share3.01.00.075.0%4.08.00.033.3%6.014.00.030.0%13.027.00.032.5%19.030.00.038.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Cellectis S.A compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0160.116-86%-0.103+742%-0.112+797%0.015+10%
Book Value Per Share--1.3091.241+5%0.944+39%1.984-34%2.577-49%
Current Ratio--1.7271.763-2%2.166-20%3.728-54%5.291-67%
Debt To Asset Ratio--0.6580.678-3%0.620+6%0.481+37%0.347+89%
Debt To Equity Ratio--1.9272.160-11%1.803+7%1.192+62%0.734+163%
Dividend Per Share----0%0.004-100%0.001-100%0.001-100%
Enterprise Value--157936000.000222704671.548-29%171881119.250-8%880355757.160-82%1507374622.619-90%
Eps--0.059-0.093+257%-0.207+449%-0.211+456%-0.195+430%
Ev To Ebitda Ratio--2.7860.405+587%-1.788+164%-6.442+331%-22.764+917%
Ev To Sales Ratio--3.1056.816-54%229.166-99%95.190-97%132.161-98%
Free Cash Flow Per Share---0.0180.048-138%-0.063+250%-0.173+868%-0.150+740%
Free Cash Flow To Equity Per Share--0.0110.268-96%0.147-92%-0.049+536%0.034-67%
Gross Profit Margin--1.0000.849+18%1.062-6%1.0040%1.065-6%
Intrinsic Value_10Y_max--8.393--------
Intrinsic Value_10Y_min---8.780--------
Intrinsic Value_1Y_max---0.152--------
Intrinsic Value_1Y_min---0.653--------
Intrinsic Value_3Y_max--0.299--------
Intrinsic Value_3Y_min---2.171--------
Intrinsic Value_5Y_max--1.664--------
Intrinsic Value_5Y_min---3.904--------
Market Cap125117500.000-20%150141000.000231407827.298-35%221958445.000-32%847233753.460-82%1088581356.330-86%
Net Profit Margin--0.466-0.710+252%-135.106+29113%-36.955+8036%-21.875+4798%
Operating Margin--0.656-0.674+203%-155.236+23757%-43.714+6762%-25.908+4048%
Operating Ratio--1.8403.452-47%136.873-99%40.167-95%24.615-93%
Pb Ratio0.955-20%1.1461.943-41%2.441-53%3.530-68%3.639-69%
Pe Ratio5.282-20%6.3383.230+96%-3.432+154%-5.462+186%-7.678+221%
Price Per Share1.250-20%1.5002.293-35%2.218-32%8.461-82%10.874-86%
Price To Free Cash Flow Ratio-17.455+17%-20.946-8.022-62%-1.299-94%-13.335-36%-18.794-10%
Price To Total Gains Ratio77.761-20%93.31341.150+127%-4.961+105%-9.220+110%-55.614+160%
Quick Ratio--2.4082.396+0%2.089+15%3.853-38%5.427-56%
Return On Assets--0.015-0.022+245%-0.095+718%-0.066+525%-0.057+467%
Return On Equity--0.045-0.061+234%-0.281+722%-0.145+422%-0.103+328%
Total Gains Per Share--0.0160.116-86%-0.100+720%-0.111+790%0.015+6%
Usd Book Value--131033000.000124865446.750+5%94448807.250+39%198688750.800-34%257966394.125-49%
Usd Book Value Change Per Share--0.0160.116-86%-0.103+742%-0.112+797%0.015+10%
Usd Book Value Per Share--1.3091.241+5%0.944+39%1.984-34%2.577-49%
Usd Dividend Per Share----0%0.004-100%0.001-100%0.001-100%
Usd Enterprise Value--157936000.000222704671.548-29%171881119.250-8%880355757.160-82%1507374622.619-90%
Usd Eps--0.059-0.093+257%-0.207+449%-0.211+456%-0.195+430%
Usd Free Cash Flow---1792000.0004594248.500-139%-6266491.500+250%-17384548.600+870%-15075800.970+741%
Usd Free Cash Flow Per Share---0.0180.048-138%-0.063+250%-0.173+868%-0.150+740%
Usd Free Cash Flow To Equity Per Share--0.0110.268-96%0.147-92%-0.049+536%0.034-67%
Usd Market Cap125117500.000-20%150141000.000231407827.298-35%221958445.000-32%847233753.460-82%1088581356.330-86%
Usd Price Per Share1.250-20%1.5002.293-35%2.218-32%8.461-82%10.874-86%
Usd Profit--5922000.000-9236453.000+256%-25548684.500+531%-22908677.500+487%-20739907.567+450%
Usd Revenue--12717000.00010414536.250+22%190613.000+6572%9665129.850+32%8673846.400+47%
Usd Total Gains Per Share--0.0160.116-86%-0.100+720%-0.111+790%0.015+6%
 EOD+3 -5MRQTTM+21 -17YOY+25 -155Y+23 -1710Y+21 -19

3.3 Fundamental Score

Let's check the fundamental score of Cellectis S.A based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-155.282
Price to Book Ratio (EOD)Between0-10.955
Net Profit Margin (MRQ)Greater than00.466
Operating Margin (MRQ)Greater than00.656
Quick Ratio (MRQ)Greater than12.408
Current Ratio (MRQ)Greater than11.727
Debt to Asset Ratio (MRQ)Less than10.658
Debt to Equity Ratio (MRQ)Less than11.927
Return on Equity (MRQ)Greater than0.150.045
Return on Assets (MRQ)Greater than0.050.015
Total7/10 (70.0%)

3.4 Technical Score

Let's check the technical score of Cellectis S.A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.250
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Cellectis S.A

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Fundamental data was last updated by Penke on 2025-04-04 12:21:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Cellectis earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Cellectis to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 46.6%Β means thatΒ $0.47 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cellectis S.A:

  • The MRQ is 46.6%. The company is making a huge profit. +2
  • The TTM is -71.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ46.6%TTM-71.0%+117.5%
TTM-71.0%YOY-13,510.6%+13,439.6%
TTM-71.0%5Y-3,695.5%+3,624.5%
5Y-3,695.5%10Y-2,187.5%-1,508.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ46.6%-99.7%+146.3%
TTM-71.0%-188.1%+117.1%
YOY-13,510.6%-199.6%-13,311.0%
5Y-3,695.5%-357.6%-3,337.9%
10Y-2,187.5%-488.5%-1,699.0%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Cellectis is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Cellectis to theΒ Biotechnology industry mean.
  • 1.5% Return on Assets means thatΒ Cellectis generatedΒ $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cellectis S.A:

  • The MRQ is 1.5%. Using its assets, the company is less efficient in making profit.
  • The TTM is -2.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ1.5%TTM-2.2%+3.8%
TTM-2.2%YOY-9.5%+7.3%
TTM-2.2%5Y-6.6%+4.3%
5Y-6.6%10Y-5.7%-0.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5%-12.3%+13.8%
TTM-2.2%-12.2%+10.0%
YOY-9.5%-12.0%+2.5%
5Y-6.6%-13.4%+6.8%
10Y-5.7%-15.3%+9.6%
4.3.1.3. Return on Equity

Shows how efficient Cellectis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Cellectis to theΒ Biotechnology industry mean.
  • 4.5% Return on Equity means Cellectis generated $0.05Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cellectis S.A:

  • The MRQ is 4.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -6.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ4.5%TTM-6.1%+10.6%
TTM-6.1%YOY-28.1%+22.0%
TTM-6.1%5Y-14.5%+8.5%
5Y-14.5%10Y-10.3%-4.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5%-16.1%+20.6%
TTM-6.1%-16.2%+10.1%
YOY-28.1%-15.8%-12.3%
5Y-14.5%-19.5%+5.0%
10Y-10.3%-21.7%+11.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Cellectis S.A.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Cellectis is operatingΒ .

  • Measures how much profit Cellectis makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Cellectis to theΒ Biotechnology industry mean.
  • An Operating Margin of 65.6%Β means the company generated $0.66 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cellectis S.A:

  • The MRQ is 65.6%. The company is operating very efficient. +2
  • The TTM is -67.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ65.6%TTM-67.4%+133.0%
TTM-67.4%YOY-15,523.6%+15,456.3%
TTM-67.4%5Y-4,371.4%+4,304.0%
5Y-4,371.4%10Y-2,590.8%-1,780.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ65.6%-188.3%+253.9%
TTM-67.4%-291.0%+223.6%
YOY-15,523.6%-214.8%-15,308.8%
5Y-4,371.4%-368.2%-4,003.2%
10Y-2,590.8%-471.9%-2,118.9%
4.3.2.2. Operating Ratio

Measures how efficient Cellectis is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 1.84 means that the operating costs are $1.84 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cellectis S.A:

  • The MRQ is 1.840. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.452. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.840TTM3.452-1.612
TTM3.452YOY136.873-133.421
TTM3.4525Y40.167-36.715
5Y40.16710Y24.615+15.552
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8402.233-0.393
TTM3.4523.152+0.300
YOY136.8733.084+133.789
5Y40.1675.091+35.076
10Y24.6156.520+18.095
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Cellectis S.A.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Cellectis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 1.73Β means the company has $1.73 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cellectis S.A:

  • The MRQ is 1.727. The company is able to pay all its short-term debts. +1
  • The TTM is 1.763. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.727TTM1.763-0.037
TTM1.763YOY2.166-0.403
TTM1.7635Y3.728-1.965
5Y3.72810Y5.291-1.564
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7273.616-1.889
TTM1.7633.893-2.130
YOY2.1664.280-2.114
5Y3.7285.791-2.063
10Y5.2916.182-0.891
4.4.3.2. Quick Ratio

Measures if Cellectis is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Cellectis to theΒ Biotechnology industry mean.
  • A Quick Ratio of 2.41Β means the company can pay off $2.41 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cellectis S.A:

  • The MRQ is 2.408. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.396. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.408TTM2.396+0.012
TTM2.396YOY2.089+0.307
TTM2.3965Y3.853-1.457
5Y3.85310Y5.427-1.574
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4082.920-0.512
TTM2.3963.417-1.021
YOY2.0894.170-2.081
5Y3.8535.727-1.874
10Y5.4276.469-1.042
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Cellectis S.A.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of CellectisΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Cellectis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.66Β means that Cellectis assets areΒ financed with 65.8% credit (debt) and the remaining percentage (100% - 65.8%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Cellectis S.A:

  • The MRQ is 0.658. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.678. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.658TTM0.678-0.019
TTM0.678YOY0.620+0.058
TTM0.6785Y0.481+0.196
5Y0.48110Y0.347+0.134
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6580.344+0.314
TTM0.6780.344+0.334
YOY0.6200.332+0.288
5Y0.4810.359+0.122
10Y0.3470.384-0.037
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Cellectis is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Cellectis to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 192.7% means that company has $1.93 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cellectis S.A:

  • The MRQ is 1.927. The company is just able to pay all its debts with equity.
  • The TTM is 2.160. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.927TTM2.160-0.233
TTM2.160YOY1.803+0.357
TTM2.1605Y1.192+0.967
5Y1.19210Y0.734+0.458
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9270.407+1.520
TTM2.1600.427+1.733
YOY1.8030.402+1.401
5Y1.1920.448+0.744
10Y0.7340.493+0.241
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Cellectis generates.

  • Above 15 is considered overpriced butΒ always compareΒ Cellectis to theΒ Biotechnology industry mean.
  • A PE ratio of 6.34 means the investor is paying $6.34Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cellectis S.A:

  • The EOD is 5.282. Based on the earnings, the company is cheap. +2
  • The MRQ is 6.338. Based on the earnings, the company is cheap. +2
  • The TTM is 3.230. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD5.282MRQ6.338-1.056
MRQ6.338TTM3.230+3.108
TTM3.230YOY-3.432+6.662
TTM3.2305Y-5.462+8.692
5Y-5.46210Y-7.678+2.216
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.282-1.809+7.091
MRQ6.338-2.564+8.902
TTM3.230-3.191+6.421
YOY-3.432-3.323-0.109
5Y-5.462-6.424+0.962
10Y-7.678-7.149-0.529
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cellectis S.A:

  • The EOD is -17.455. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -20.946. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.022. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-17.455MRQ-20.946+3.491
MRQ-20.946TTM-8.022-12.924
TTM-8.022YOY-1.299-6.723
TTM-8.0225Y-13.335+5.313
5Y-13.33510Y-18.794+5.459
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-17.455-2.461-14.994
MRQ-20.946-3.566-17.380
TTM-8.022-3.951-4.071
YOY-1.299-4.482+3.183
5Y-13.335-8.693-4.642
10Y-18.794-9.796-8.998
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Cellectis is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 1.15 means the investor is paying $1.15Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cellectis S.A:

  • The EOD is 0.955. Based on the equity, the company is cheap. +2
  • The MRQ is 1.146. Based on the equity, the company is underpriced. +1
  • The TTM is 1.943. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.955MRQ1.146-0.191
MRQ1.146TTM1.943-0.797
TTM1.943YOY2.441-0.497
TTM1.9435Y3.530-1.587
5Y3.53010Y3.639-0.109
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.9551.676-0.721
MRQ1.1462.283-1.137
TTM1.9432.457-0.514
YOY2.4412.507-0.066
5Y3.5303.773-0.243
10Y3.6394.321-0.682
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-12-312024-03-312024-06-302024-09-302024-12-31
Other Assets  00000299299-300-1
Income Tax Expense  -759-1,422-2,181592-1,589-312-1,9012,415514



6.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets383,544
Total Liabilities252,511
Total Stockholder Equity131,033
 As reported
Total Liabilities 252,511
Total Stockholder Equity+ 131,033
Total Assets = 383,544

Assets

Total Assets383,544
Total Current Assets287,069
Long-term Assets96,476
Total Current Assets
Cash And Cash Equivalents 143,251
Short-term Investments 117,055
Net Receivables 23,037
Other Current Assets 3,726
Total Current Assets  (as reported)287,069
Total Current Assets  (calculated)287,069
+/-0
Long-term Assets
Property Plant Equipment 75,863
Long Term Investments 7,521
Intangible Assets 1,115
Long-term Assets Other 11,595
Long-term Assets  (as reported)96,476
Long-term Assets  (calculated)96,094
+/- 382

Liabilities & Shareholders' Equity

Total Current Liabilities166,269
Long-term Liabilities86,242
Total Stockholder Equity131,033
Total Current Liabilities
Short-term Debt 13,226
Short Long Term Debt 4,841
Accounts payable 18,664
Other Current Liabilities 22,202
Total Current Liabilities  (as reported)166,269
Total Current Liabilities  (calculated)58,933
+/- 107,336
Long-term Liabilities
Long term Debt 43,990
Capital Lease Obligations 42,630
Long-term Liabilities Other 882
Long-term Liabilities  (as reported)86,242
Long-term Liabilities  (calculated)87,502
+/- 1,260
Total Stockholder Equity
Common Stock5,889
Retained Earnings -329,607
Accumulated Other Comprehensive Income -39,537
Other Stockholders Equity 494,288
Total Stockholder Equity (as reported)131,033
Total Stockholder Equity (calculated)131,033
+/-0
Other
Capital Stock5,889
Cash and Short Term Investments 260,306
Common Stock Shares Outstanding 90,566
Current Deferred Revenue112,161
Liabilities and Stockholders Equity 383,544
Net Debt -51,790
Net Invested Capital 179,864
Net Working Capital 120,800
Property Plant and Equipment Gross 167,244
Short Long Term Debt Total 91,461



6.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-06-302011-12-312010-12-312010-06-302009-12-312009-06-302008-12-31
> Total Assets 
60,832
58,934
91,339
72,336
69,231
131,886
117,351
115,106
89,557
90,933
39,081
44,113
55,435
58,594
173,678
167,340
367,939
344,650
339,956
372,884
356,593
358,602
352,469
330,678
325,847
328,639
349,395
332,882
324,048
534,066
519,799
500,840
511,938
505,323
480,475
467,469
471,135
472,696
484,957
469,471
442,712
457,565
412,886
382,076
347,191
320,883
279,580
261,216
251,408
227,674
209,700
333,995
354,131
406,908
395,876
383,544
383,544395,876406,908354,131333,995209,700227,674251,408261,216279,580320,883347,191382,076412,886457,565442,712469,471484,957472,696471,135467,469480,475505,323511,938500,840519,799534,066324,048332,882349,395328,639325,847330,678352,469358,602356,593372,884339,956344,650367,939167,340173,67858,59455,43544,11339,08190,93389,557115,106117,351131,88669,23172,33691,33958,93460,832
   > Total Current Assets 
48,143
44,447
74,758
54,937
47,567
70,627
54,362
51,467
30,545
31,015
26,993
27,541
49,215
50,146
166,594
160,515
359,005
337,074
332,832
365,401
341,136
339,455
333,471
311,786
306,306
308,602
338,707
323,222
313,958
524,576
509,491
487,641
459,555
439,163
410,734
391,520
377,931
347,927
345,718
315,362
272,387
280,352
235,849
225,429
195,175
175,167
140,272
143,811
137,365
113,284
96,495
232,813
257,834
305,623
294,372
287,069
287,069294,372305,623257,834232,81396,495113,284137,365143,811140,272175,167195,175225,429235,849280,352272,387315,362345,718347,927377,931391,520410,734439,163459,555487,641509,491524,576313,958323,222338,707308,602306,306311,786333,471339,455341,136365,401332,832337,074359,005160,515166,59450,14649,21527,54126,99331,01530,54551,46754,36270,62747,56754,93774,75844,44748,143
       Cash And Cash Equivalents 
39,781
37,983
65,326
46,509
31,983
54,934
35,240
28,841
12,228
12,415
10,231
10,438
27,853
27,578
141,790
136,615
128,204
318,415
314,332
343,557
215,777
202,440
209,010
290,497
237,200
231,827
263,862
296,982
241,363
471,215
475,775
451,889
421,457
396,967
342,485
360,907
287,133
260,710
260,941
268,239
207,457
248,226
210,709
186,135
154,868
129,440
119,008
97,697
83,515
85,505
67,358
136,595
122,857
148,954
159,087
143,251
143,251159,087148,954122,857136,59567,35885,50583,51597,697119,008129,440154,868186,135210,709248,226207,457268,239260,941260,710287,133360,907342,485396,967421,457451,889475,775471,215241,363296,982263,862231,827237,200290,497209,010202,440215,777343,557314,332318,415128,204136,615141,79027,57827,85310,43810,23112,41512,22828,84135,24054,93431,98346,50965,32637,98339,781
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
97,602
97,578
87,131
36,509
39,066
39,990
40,240
40,602
40,700
19,872
139
388
382
389
20,381
20,385
59,005
50,378
41,242
27,091
18,438
3,393
393
499
0
23,687
21,359
7,907
4,647
1,120
0
67,052
90,045
123,692
101,619
117,055
117,055101,619123,69290,04567,05201,1204,6477,90721,35923,68704993933,39318,43827,09141,24250,37859,00520,38520,38138938238813919,87240,70040,60240,24039,99039,06636,50987,13197,57897,60200000000000000000000
       Net Receivables 
5,030
3,610
2,523
6,972
12,075
10,984
18,281
21,689
4,563
18,107
3,637
16,134
3,219
17,295
7,422
19,641
0
10,497
10,203
16,549
20,714
31,272
29,623
12,323
19,536
22,624
21,896
12,277
17,927
19,651
19,222
20,144
24,102
27,723
31,515
12,099
17,866
12,825
12,400
15,874
21,427
11,948
10,231
29,629
33,760
15,532
12,954
15,268
21,870
19,910
21,973
23,111
40,397
26,338
27,810
23,037
23,03727,81026,33840,39723,11121,97319,91021,87015,26812,95415,53233,76029,62910,23111,94821,42715,87412,40012,82517,86612,09931,51527,72324,10220,14419,22219,65117,92712,27721,89622,62419,53612,32329,62331,27220,71416,54910,20310,497019,6417,42217,2953,21916,1343,63718,1074,56321,68918,28110,98412,0756,9722,5233,6105,030
       Inventory 
168
170
169
172
203
811
841
935
486
493
497
507
380
377
170
164
0
200
200
173
117
139
119
118
113
130
125
250
203
231
223
275
1,054
986
3,344
2,897
3,591
5,710
6,262
1,606
5,315
2,468
1,674
0
6,548
30,194
-21,159
21,768
26,960
0
6,906
0
0
0
623
0
06230006,906026,96021,768-21,15930,1946,54801,6742,4685,3151,6066,2625,7103,5912,8973,3449861,0542752232312032501251301131181191391171732002000164170377380507497493486935841811203172169170168
       Other Current Assets 
3,164
2,684
2,324
1,284
3,306
3,897
0
1
13,269
-1
12,629
463
17,764
352
17,212
1,781
359,005
7,962
8,097
5,122
811
775
740
8,849
694
2,902
1,263
13,713
1
-2
-1
15,333
1
16,496
15,321
15,617
1
21,786
24,873
29,643
-1
1
439
9,665
-1
1
8,310
9,078
373
7,869
258
6,055
68,577
6,639
5,609
3,726
3,7265,6096,63968,5776,0552587,8693739,0788,3101-19,6654391-129,64324,87321,786115,61715,32116,496115,333-1-2113,7131,2632,9026948,8497407758115,1228,0977,962359,0051,78117,21235217,76446312,629-113,269103,8973,3061,2842,3242,6843,164
   > Long-term Assets 
12,689
14,487
16,581
17,399
21,664
61,260
62,989
63,638
59,012
59,920
12,088
16,572
6,220
8,448
7,084
6,825
8,934
7,576
7,125
7,483
15,456
19,147
18,997
18,892
19,541
20,036
10,688
9,661
10,090
9,490
10,308
13,199
52,382
66,161
69,740
75,949
93,204
124,769
139,239
154,109
170,325
177,214
177,037
156,647
152,016
145,716
139,307
117,406
114,042
114,389
113,205
101,182
96,297
101,284
101,205
96,476
96,476101,205101,28496,297101,182113,205114,389114,042117,406139,307145,716152,016156,647177,037177,214170,325154,109139,239124,76993,20475,94969,74066,16152,38213,19910,3089,49010,0909,66110,68820,03619,54118,89218,99719,14715,4567,4837,1257,5768,9346,8257,0848,4486,22016,57212,08859,92059,01263,63862,98961,26021,66417,39916,58114,48712,689
       Property Plant Equipment 
1,988
1,223
1,272
1,214
5,204
8,579
7,409
7,253
6,487
6,587
5,237
5,343
3,963
3,924
3,294
3,173
0
5,747
5,495
5,514
13,210
16,903
16,986
16,862
17,171
17,691
8,227
7,226
7,689
7,435
8,300
10,041
46,476
60,195
63,151
69,324
84,625
116,323
128,384
145,518
146,615
153,528
152,440
148,269
143,752
135,039
128,871
107,896
105,143
100,688
95,919
92,665
87,757
83,992
81,180
75,863
75,86381,18083,99287,75792,66595,919100,688105,143107,896128,871135,039143,752148,269152,440153,528146,615145,518128,384116,32384,62569,32463,15160,19546,47610,0418,3007,4357,6897,2268,22717,69117,17116,86216,98616,90313,2105,5145,4955,74703,1733,2943,9243,9635,3435,2376,5876,4877,2537,4098,5795,2041,2141,2721,2231,988
       Goodwill 
0
0
0
0
0
0
0
38,034
34,630
35,134
1,483
1,512
0
0
0
0
0
0
0
0
0
2
-3
0
-1
4
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0000000000001000-100000000000004-10-320000000001,5121,48335,13434,63038,0340000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
356
886
953
989
0
897
0
0
0
4,684
4,755
5,468
5,517
7,484
7,376
9,781
7,007
22,105
22,101
22,045
6,524
6,567
9,093
8,926
8,791
8,185
13,006
11,184
7,853
2,315
2,242
2,169
7,521
7,5212,1692,2422,3157,85311,18413,0068,1858,7918,9269,0936,5676,52422,04522,10122,1057,0079,7817,3767,4845,5175,4684,7554,684000897098995388635600000000000000000000000
       Intangible Assets 
24
0
23
0
5,288
45,625
0
50,019
4,734
48,880
4,779
7,631
1,516
3,790
1,295
1,249
0
1,083
1,075
1,045
1,316
1,408
1,326
1,340
1,424
1,384
1,470
1,431
1,505
1,386
1,352
1,268
1,222
1,209
1,120
1,108
1,094
1,071
1,074
1,585
1,604
1,584
2,551
1,853
1,698
1,584
1,511
718
713
695
662
672
677
653
689
1,115
1,1156896536776726626957137181,5111,5841,6981,8532,5511,5841,6041,5851,0741,0711,0941,1081,1201,2091,2221,2681,3521,3861,5051,4311,4701,3841,4241,3401,3261,4081,3161,0451,0751,08301,2491,2953,7901,5167,6314,77948,8804,73450,019045,6255,288023024
       Long-term Assets Other 
1
0
0
0
0
1
0
0
11,350
1
0
1
0
0
2,272
0
8,934
1
1
1
0
0
0
0
0
2
2
102
-1
2
-1
-1
52,382
2
1
75,949
1
-1
0
-1
1
1
1
3
-1
-136,623
-1
1
1
800
4,656
7,851
4,655
9,746
11,825
11,595
11,59511,8259,7464,6557,8514,65680011-1-136,623-13111-10-1175,9491252,382-1-12-110222000001118,93402,2720010111,35000100001
> Total Liabilities 
14,621
15,840
18,119
12,637
19,104
94,865
26,813
33,420
34,176
34,702
35,674
37,463
35,172
31,376
98,551
94,955
367,939
71,854
70,390
84,669
77,871
73,817
66,316
56,632
54,491
57,197
49,257
46,978
47,310
45,292
48,479
50,569
79,632
100,215
98,704
111,999
100,548
127,637
158,747
160,625
152,968
155,242
150,739
145,602
144,137
140,362
133,968
135,275
130,919
131,116
133,577
249,369
263,649
258,385
266,452
252,511
252,511266,452258,385263,649249,369133,577131,116130,919135,275133,968140,362144,137145,602150,739155,242152,968160,625158,747127,637100,548111,99998,704100,21579,63250,56948,47945,29247,31046,97849,25757,19754,49156,63266,31673,81777,87184,66970,39071,854367,93994,95598,55131,37635,17237,46335,67434,70234,17633,42026,81394,86519,10412,63718,11915,84014,621
   > Total Current Liabilities 
12,781
14,233
15,442
10,787
17,020
26,959
22,359
28,356
29,137
29,585
30,515
32,201
30,712
26,960
94,485
91,037
84,880
71,312
69,886
84,119
77,295
73,147
65,621
56,043
53,880
56,524
48,543
43,534
43,736
42,008
45,362
46,869
47,054
51,821
51,381
62,604
49,008
53,052
56,613
52,015
46,922
51,446
49,603
49,348
52,337
55,282
53,030
62,995
60,468
42,047
43,954
155,016
158,300
159,539
165,258
166,269
166,269165,258159,539158,300155,01643,95442,04760,46862,99553,03055,28252,33749,34849,60351,44646,92252,01556,61353,05249,00862,60451,38151,82147,05446,86945,36242,00843,73643,53448,54356,52453,88056,04365,62173,14777,29584,11969,88671,31284,88091,03794,48526,96030,71232,20130,51529,58529,13728,35622,35926,95917,02010,78715,44214,23312,781
       Short-term Debt 
0
0
1,072
0
745
1,572
1,588
1,307
448
1,265
203
954
1,122
1,684
752
1,048
0
3,401
3,354
2,100
2,149
2,417
2,156
1,726
405
70
29
21
82
772
277
333
5,385
2,104
2,996
1,067
1,342
3,777
4,331
6,696
6,985
7,691
8,079
10,683
11,893
12,932
18,350
12,960
13,249
13,455
13,137
13,664
13,449
13,345
13,725
13,226
13,22613,72513,34513,44913,66413,13713,45513,24912,96018,35012,93211,89310,6838,0797,6916,9856,6964,3313,7771,3421,0672,9962,1045,385333277772822129704051,7262,1562,4172,1492,1003,3543,40101,0487521,6841,1229542031,2654481,3071,5881,57274501,07200
       Short Long Term Debt 
0
0
0
0
0
0
0
1,316
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
64
55
54
44
25
347
111
0
0
643
2,104
2,996
1,067
1,342
0
4,331
0
0
0
0
2,246
3,485
4,841
10,379
5,088
5,068
5,185
4,934
5,162
5,045
4,988
5,217
4,841
4,8415,2174,9885,0455,1624,9345,1855,0685,08810,3794,8413,4852,24600004,33101,3421,0672,9962,1046430011134725445455640000000000000001,3160000000
       Accounts payable 
7,478
6,429
6,778
5,989
11,257
25,387
20,771
27,048
15,273
28,321
13,129
12,977
12,073
11,954
12,371
11,919
0
5,998
7,499
7,228
8,967
12,596
10,294
9,700
13,005
17,205
12,693
9,460
11,254
12,734
15,597
15,883
15,698
19,760
19,761
29,264
26,873
32,674
35,003
24,609
24,682
28,254
22,809
23,762
20,921
24,159
22,353
21,456
22,324
19,229
20,476
19,069
16,051
18,213
18,511
18,664
18,66418,51118,21316,05119,06920,47619,22922,32421,45622,35324,15920,92123,76222,80928,25424,68224,60935,00332,67426,87329,26419,76119,76015,69815,88315,59712,73411,2549,46012,69317,20513,0059,70010,29412,5968,9677,2287,4995,998011,91912,37111,95412,07312,97713,12928,32115,27327,04820,77125,38711,2575,9896,7786,4297,478
       Other Current Liabilities 
5,303
7,805
-1,206
4,798
342
0
0
1
13,415
-1
17,183
10,519
17,517
6,199
81,362
5,726
84,880
6,425
9,704
14,924
9,323
8,502
6,171
5,777
5,089
6,527
6,058
7,997
7,296
8,102
9,236
9,899
5,691
9,572
9,038
12,240
20,250
16,118
16,839
20,258
14,991
15,078
18,215
14,602
18,942
17,791
12,007
28,520
24,553
9,122
10,224
12,086
8,253
10,099
10,174
22,202
22,20210,17410,0998,25312,08610,2249,12224,55328,52012,00717,79118,94214,60218,21515,07814,99120,25816,83916,11820,25012,2409,0389,5725,6919,8999,2368,1027,2967,9976,0586,5275,0895,7776,1718,5029,32314,9249,7046,42584,8805,72681,3626,19917,51710,51917,183-113,4151003424,798-1,2067,8055,303
   > Long-term Liabilities 
1,840
1,606
2,676
1,850
2,084
67,906
4,454
5,064
5,039
5,117
5,159
5,263
4,460
4,416
4,066
3,918
572
543
504
550
576
670
694
589
611
673
714
3,444
3,574
3,284
3,117
3,700
32,578
48,394
47,323
49,395
51,540
74,585
102,134
108,610
106,046
103,796
101,136
96,254
91,800
85,080
80,938
72,280
70,451
89,069
89,623
94,353
105,348
98,846
100,801
86,242
86,242100,80198,846105,34894,35389,62389,06970,45172,28080,93885,08091,80096,254101,136103,796106,046108,610102,13474,58551,54049,39547,32348,39432,5783,7003,1173,2843,5743,4447146736115896946705765505045435723,9184,0664,4164,4605,2635,1595,1175,0395,0644,45467,9062,0841,8502,6761,6061,840
       Other Liabilities 
0
0
0
0
0
0
0
1,035
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
532
551
650
697
2,566
3,309
3,053
2,908
2,682
2,315
2,684
2,857
2,855
2,841
9,721
34,777
8,627
7,927
4,597
5,927
5,957
4,947
4,056
3,821
9,353
0
14,944
0
0
0
0
0
0
00000014,94409,3533,8214,0564,9475,9575,9274,5977,9278,62734,7779,7212,8412,8552,8572,6842,3152,6822,9083,0533,3092,5666976505515320000000000000001,0350000000
> Total Stockholder Equity
46,211
43,094
73,221
59,699
50,128
37,022
87,634
78,927
53,073
53,889
3,708
6,949
21,181
28,126
76,716
73,917
283,592
272,613
269,271
287,423
277,782
283,489
284,503
272,175
269,236
267,875
282,405
266,791
255,324
447,728
430,648
409,301
391,150
363,824
340,636
315,123
331,843
307,606
290,369
275,573
261,926
275,865
237,967
221,293
191,044
168,933
136,641
117,968
113,735
96,558
76,123
84,625
90,482
148,523
129,424
131,033
131,033129,424148,52390,48284,62576,12396,558113,735117,968136,641168,933191,044221,293237,967275,865261,926275,573290,369307,606331,843315,123340,636363,824391,150409,301430,648447,728255,324266,791282,405267,875269,236272,175284,503283,489277,782287,423269,271272,613283,59273,91776,71628,12621,1816,9493,70853,88953,07378,92787,63437,02250,12859,69973,22143,09446,211
   Common Stock
46,211
672
834
710
777
104,202
167,093
174,551
1,312
171,715
1,427
1,455
1,728
1,711
1,858
1,790
281,331
1,966
1,975
1,923
1,996
1,965
1,982
1,858
1,888
2,051
2,365
2,367
2,374
2,764
2,765
2,765
2,765
2,766
2,766
2,767
2,767
2,768
2,768
2,785
2,801
2,947
2,946
2,945
2,945
2,946
2,949
2,955
3,487
3,491
3,492
4,361
4,372
5,894
5,906
5,889
5,8895,9065,8944,3724,3613,4923,4913,4872,9552,9492,9462,9452,9452,9462,9472,8012,7852,7682,7682,7672,7672,7662,7662,7652,7652,7652,7642,3742,3672,3652,0511,8881,8581,9821,9651,9961,9231,9751,966281,3311,7901,8581,7111,7281,4551,427171,7151,312174,551167,093104,20277771083467246,211
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
171
0
-5,519
-4,255
0
-36,285
0
-66,719
-93,578
-95,015
1,121
-94,220
-181,662
-175,722
-960
-162,092
0
-1,672
-2,390
-1,783
-3,996
-1,680
-2,169
2,630
1,520
-3,466
-530
1,978
6,097
-11,534
-13,561
-16,668
-22,385
-18,903
-30,518
-22,640
-29,254
-23,730
-13,556
-4,089
-12,363
-9,602
-14,345
-18,021
-21,261
-29,626
-35,434
-28,605
-28,542
-37,050
-37,505
-36,660
-37,209
-38,055
-35,154
-39,537
-39,537-35,154-38,055-37,209-36,660-37,505-37,050-28,542-28,605-35,434-29,626-21,261-18,021-14,345-9,602-12,363-4,089-13,556-23,730-29,254-22,640-30,518-18,903-22,385-16,668-13,561-11,5346,0971,978-530-3,4661,5202,630-2,169-1,680-3,996-1,783-2,390-1,6720-162,092-960-175,722-181,662-94,2201,121-95,015-93,578-66,7190-36,2850-4,255-5,5190171
   Capital Surplus 00000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
-171
46,305
89,035
63,244
60,074
36,287
-1
0
167,804
-1
180,681
183,992
211,359
208,319
243,063
234,194
2,261
444,103
456,385
459,731
491,933
498,492
516,180
497,453
519,167
568,029
604,249
613,741
625,260
815,776
823,353
828,525
831,282
834,830
839,438
843,478
846,839
849,322
851,348
863,912
869,695
920,591
925,290
934,695
937,333
567,283
579,047
583,122
608,084
476,224
473,327
522,354
523,514
606,146
607,153
494,288
494,288607,153606,146523,514522,354473,327476,224608,084583,122579,047567,283937,333934,695925,290920,591869,695863,912851,348849,322846,839843,478839,438834,830831,282828,525823,353815,776625,260613,741604,249568,029519,167497,453516,180498,492491,933459,731456,385444,1032,261234,194243,063208,319211,359183,992180,681-1167,8040-136,28760,07463,24489,03546,305-171



6.4. Balance Sheets

Currency in USD. All numbers in thousands.




6.5. Cash Flows

Currency in USD. All numbers in thousands.




6.6. Income Statements

Currency in USD. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue41,506
Cost of Revenue-0
Gross Profit41,50641,506
 
Operating Income (+$)
Gross Profit41,506
Operating Expense-101,060
Operating Income-59,554-59,554
 
Operating Expense (+$)
Research Development90,536
Selling General Administrative17,602
Selling And Marketing Expenses0
Operating Expense101,060108,138
 
Net Interest Income (+$)
Interest Income11,278
Interest Expense-7,453
Other Finance Cost-0
Net Interest Income3,825
 
Pretax Income (+$)
Operating Income-59,554
Net Interest Income3,825
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-36,761-82,347
EBIT - interestExpense = -36,761
-36,761
-29,308
Interest Expense7,453
Earnings Before Interest and Taxes (EBIT)-29,308-29,308
Earnings Before Interest and Taxes (EBITDA)-9,462
 
After tax Income (+$)
Income Before Tax-36,761
Tax Provision-0
Net Income From Continuing Ops-36,761-36,761
Net Income-36,761
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses101,060
Total Other Income/Expenses Net22,793-3,825
 

Technical Analysis of Cellectis
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cellectis. The general trend of Cellectis is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cellectis's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Cellectis Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cellectis S.A.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.25 < 1.25 < 1.25.

The bearish price targets are: 1.25 > 1.25 > 1.25.

Know someone who trades $CMVLF? Share this with them.πŸ‘‡

Cellectis S.A Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cellectis S.A. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cellectis S.A Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cellectis S.A.

Cellectis S.A Daily Moving Average Convergence/Divergence (MACD) ChartCellectis S.A Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cellectis S.A. The current adx is .

Cellectis S.A Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cellectis S.A.

Cellectis S.A Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cellectis S.A.

Cellectis S.A Daily Relative Strength Index (RSI) ChartCellectis S.A Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cellectis S.A.

Cellectis S.A Daily Stochastic Oscillator ChartCellectis S.A Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cellectis S.A.

Cellectis S.A Daily Commodity Channel Index (CCI) ChartCellectis S.A Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cellectis S.A.

Cellectis S.A Daily Chande Momentum Oscillator (CMO) ChartCellectis S.A Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cellectis S.A.

Cellectis S.A Daily Williams %R ChartCellectis S.A Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Cellectis S.A.

Cellectis S.A Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cellectis S.A.

Cellectis S.A Daily Average True Range (ATR) ChartCellectis S.A Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cellectis S.A.

Cellectis S.A Daily On-Balance Volume (OBV) ChartCellectis S.A Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cellectis S.A.

Cellectis S.A Daily Money Flow Index (MFI) ChartCellectis S.A Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cellectis S.A.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-12-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-02ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Cellectis S.A Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cellectis S.A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.250
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Cellectis with someone you think should read this too:
  • Are you bullish or bearish on Cellectis? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cellectis? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cellectis S.A

I send you an email if I find something interesting about Cellectis S.A.


Comments

How you think about this?

Leave a comment

Stay informed about Cellectis S.A.

Receive notifications about Cellectis S.A in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.